MedTrace Logo

Study of LX6171 in Elderly Volunteers With Age Associated Memory Impairment

NCT00691808 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 103

Last updated 2010-03-03

Study results available
· View outcomes & findings →

Summary

The purpose of the study is to determine the safety, tolerability, and effectiveness of 2 dose levels of LX6171 given over 28 days in patients with Age Associated Memory Impairment (AAMI).

Conditions

  • Age-Related Memory Disorders

Interventions

DRUG

LX6171 High Dose

A high dose of LX6171, using an oral suspension; daily oral intake for 28 days in the morning at approximately the same time.

DRUG

LX6171 Low Dose

A low dose of LX6171, using an oral suspension; daily oral intake for 28 days in the morning at approximately the same time.

DRUG

Placebo

Matching placebo dosing with daily oral intake for 28 days in the morning at approximately the same time.

Sponsors & Collaborators

  • Lexicon Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Philip M. Brown, M.D., J.D. · Lexicon Pharmaceuticals, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
60 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-02-29
Primary Completion
2008-10-31

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00691808 on ClinicalTrials.gov